The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Diagnosis, management and screening of early localised prostate cancer.
Open accessAbstract
The incidence of prostate cancer is rising worldwide, caused mainly by demographic factors, particularly the increasingly elderly population and, more importantly, the increasing number of cases identified following prostate specific antigen (PSA) testing. It is commonly quoted that many more men die with prostate cancer than of it. Autopsy/post-mortem studies show that while a very high proportion of elderly men have histological evidence of the disease, a much smaller proportion develop clinically apparent cancer. The natural history of prostate cancer is poorly understood, but progression appears to be related to stage and grade of tumour. Prostate cancer can be diagnosed by digital rectal examination (DRE), serum PSA test, and/or transrectal ultrasound (TRUS), with confirmation by biopsy. Each test identifies a proportion of cancers, with higher rates of detection when they are used in combination. The tests are also used to determine which tumours are localised within the prostate and are, thus, potentially treatable. Unfortunately, clinical staging is unreliable, with approximately one half of all tumours upstaged following surgery. Three major treatment options are available for localised prostate cancer: radical prostatectomy, radical radiotherapy and conservative management (involving monitoring and treatment of symptoms). Although radical treatment rates are rising, good quality evidence concerning their comparative effectiveness and cost-effectiveness is lacking. Observational studies of highly selected patient groups suggests that there may be a slightly lower mortality rate following radical treatments compared with conservative management, but there has been very little research into treatment complications and quality of life of men after any of the treatments. In the past, investigations of prostate cancer were reserved largely for patients exhibiting symptoms, but the introduction of the PSA test has opened up the possibility of screening healthy men for the disease. Observational studies suggest that DRE and PSA, combined with TRUS and biopsy, can identify localised prostate cancer in 3-5% of men, although the tests do result in a number of false positives and negatives. Major questions remain concerning the natural history of the disease, potential costs (financial, social and psychological) of a screening programme, and the effectiveness and cost-effectiveness of treatments for localised disease. The lack of good quality data and the strength of these concerns means that population screening for prostate cancer cannot be recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Methods for the economic evaluation of health care programmes
Wilson, S. H. (1987) · Journal of Epidemiology and Community Health · doi:10.1136/jech.41.4.355-a · Cited by 4,275
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35233-3 · Cited by 1,592
Random Systematic Versus Directed Ultrasound Guided Transrectal Core Biopsies of the Prostate
Hodge, K. K., McNeal, J. E., Terris, M. K., & Stamey, T. A. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)38664-0 · Cited by 1,571
Principles and Practice of Screening for Disease.
Zavon, M. R. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130131020 · Cited by 1,356
Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., & Walsh, P. C. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35410-1 · Cited by 1,278
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Catalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
Results of Conservative Management of Clinically Localized Prostate Cancer
Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J.-E., Adolfsson, J., Jones, G. W., Chisholm, G. D., Moskovitz, B., Livne, P. M., & Warner, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300403 · Cited by 928
Cited by
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Donovan, J., Little, P., Mills, N., Smith, M., Brindle, L., Jacoby, A., Peters, T., Frankel, S., Neal, D., & Hamdy, F. (2002) · BMJ · doi:10.1136/bmj.325.7367.766 · Cited by 533
Quinn, M., & Babb, P. (2002) · BJU International · doi:10.1046/j.1464-410x.2002.2822.x · Cited by 446
Dinnes, J., Deeks, J., Kirby, J., & Roderick, P. (2005) · Health Technology Assessment · doi:10.3310/hta9120 · Cited by 438
Development and validation of methods for assessing the quality of diagnostic accuracy studies
Whiting, P., Rutjes, A., Dinnes, J., Reitsma, J., Bossuyt, P., & Kleijnen, J. (2004) · Health Technology Assessment · doi:10.3310/hta8250 · Cited by 372
Metadata
- Authors
- Selley, Donovan, Faulkner, Coast, & Gillatt
- Venue
- Health Technology Assessment
- Published
- 1997
- Volume
- 1
- Issue
- 2
- Pages
- i, 1-96
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W3142152021
- Cited by
- 277
- References
- 84
- FWCI
- 12.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis, management and screening of early localised prostate cancer. https://app.cochat.ai/papers/10.3310/hta1020
- The paper
- Selley, Donovan, Faulkner, Coast, & Gillatt. (1997). Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment. https://doi.org/10.3310/hta1020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.